Moderna Hits Fresh 52-Week High as Bernstein Calls Intismeran Clearest mRNA Platform Validation, Keeps $45 Target

Moderna Inc. (NASDAQ: MRNA) shares set a fresh 52-week high Friday before giving back the intraday advance, while Bernstein SocGen Group reiterated its Market Perform rating and $45 price target and called intismeran the clearest validation yet of Moderna’s broader mRNA therapeutics platform.

Visit Website